Search
SOLACI Congress
HomeFile

File

View Category
Calcified Lesions

EuroPCR 2025 | EMPOWER CAD

Women are underrepresented in numerous percutaneous transluminal coronary angioplasty (PTCA) studies, particularly in those analyzing calcified or...
Dr. Carlos Fava -
Learn More
Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...
Dr. Andrés Rodríguez -
Learn More
Coronary disease

EuroPCR 2025 | BALI Trial: Intravascular Lithotripsy vs. Conventional Lesion Preparation in Calcified Lesions

Severely calcified coronary lesions represent a therapeutic challenge and have been associated with higher rates of failed...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

Patients with extensive acute myocardial infarctions may develop cardiogenic shock, which has been associated with marked contractile...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

EuroPCR 2025 | 10-Year Follow-up of DANAMI-3-PRIMULTI: Complete vs. Culprit-Only Revascularization in STEMI with Multivessel Disease

The DANAMI-3-PRIMULTI trial included 627 patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD),...
solaci -
Learn More
Structural heart disease

EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI)

Coronary artery disease is present in 50 to 70% of TAVI candidates and over 90% of these...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Platelet inhibition during and after coronary angioplasty is essential to prevent peri- and post-procedural ischemic events. To...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy